Salmon Calcitonin in the Treatment of Postmenopausal Osteoporosis
Authors: VAHAB FATOURECHI
Journal: Annals of Internal Medicine (1987)

Editorials1 December 1987Salmon Calcitonin in the Treatment of Postmenopausal OsteoporosisVAHAB FATOURECHI, M.D., HUNTER HEATH III, M.D.VAHAB FATOURECHI, M.D.Search for more papers by this author, HUNTER HEATH III, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-107-6-923 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPostmenopausal osteoporosis is a common disorder and a major public health problem (1). It is hoped that appropriate intervention will reduce morbidity and mortality resulting from vertebral and hip fractures complicating the disease. The National Institutes of Health Consensus Conference on Osteoporosis (2) has recommended a calcium intake of 1000 to 1500 mg per day for all postmenopausal women and has advised that postmenopausal estrogen replacement therapy should be considered individually by the patient and her physician. This preventive approach is supported by extensive basic, clinical, and epidemiologic research (3), and the therapeutic benefit of estrogen in established postmenopausal osteoporosis...References1. RIGGSMELTON BL. Involutional osteoporosis. N Engl J Med. 1986;314:1676-86. CrossrefMedlineGoogle Scholar2. Consensus Conference on Osteoporosis. JAMA. 1984;252:799-802. CrossrefMedlineGoogle Scholar3. CHESTNUT C. An appraisal of the role of estrogens in the treatment of postmenopausal osteoporosis. J Am Ger Soc. 1984;32:604-8. CrossrefMedlineGoogle Scholar4. JUDDMELDRUMDEFTOSHENDERSON HDLB. Estrogen replacement indications and complications. Ann Intern Med. 1983;98:195-205. LinkGoogle Scholar5. BIKLE D. Fluoride treatment of osteoporosis: a new look at an old drug. Ann Intern Med. 1983;98:1013-5. LinkGoogle Scholar6. AUSTINHEATH LH. Calcitonin: physiology and pathophysiology. N Engl J Med. 1980;304:269-78. CrossrefGoogle Scholar7. TAGGARTCHESNUTIVEY HMCJ. Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis. Lancet. 1982;1:475-8. CrossrefMedlineGoogle Scholar8. TIEGSBODYBARTAHEATH RJJH. Secretion and metabolism of monomeric human calcitonin: effects of age, sex, and thyroid damage. J Bone Min Res. 1986:1:339-49. CrossrefMedlineGoogle Scholar9. TIEGSBODYWAHNERBARTARIGGSHEATH RJHJBH. Calcitonin secretion in postmenopausal osteoporosis. N Engl J Med. 1985;312:1097-100. CrossrefMedlineGoogle Scholar10. HURLEYTIEGSWAHNERHEATH DRHH. Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin. N Engl J Med. 1987;317:537-41. CrossrefMedlineGoogle Scholar11. FRANCESCHINIBOTTAROPANOPOULOSMESSINA RPCV. Long-term treatment with salmon calcitonin in postmenopausal osteoporosis. Current Ther Res. 1983;34:795-800. Google Scholar12. WALLACHCOHNATKINS SSH. Effect of salmon calcitonin on skeletal mass in osteoporosis. Current Ther Res. 1977;22:556-72. Google Scholar13. GRUBERIVEYBAYLINK HJD. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism. 1984;33:295-303. CrossrefMedlineGoogle Scholar14. GENNARICHIERICHETTIBIGAZZI CSS. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Current Ther Res. 1985;38:455-64. Google Scholar15. MAZZUOLIPASSERIGENNARI GMC. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int. 1986;38:3-8. CrossrefMedlineGoogle Scholar16. ALOIAVASWANIKAPOORYEHCOHN JAAJS. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism. 1985;34:124-9. CrossrefMedlineGoogle Scholar17. JOWSEYRIGGSKELLYHOFFMAN JBPD. Calcium and salmon calcitonin treatment of osteoporosis. J Clin Endocrinol Metab. 1978;47:633-9. CrossrefMedlineGoogle Scholar18. MARIECAULIN PF. Mechanisms underlying the effects of phosphate and calcitonin on bone histology in postmenopausal osteoporosis. Bone. 1986;7:17-22. CrossrefMedlineGoogle Scholar19. HODGSON S. Skeletal remodeling and renal osteodystrophy. Semin Nephrol. 1986;6:42-55. MedlineGoogle Scholar20. PARFITT A. Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Min Electrolyte Metab. 1980;4:273-87. Google Scholar21. REGINSTERALBERTFRANCHIMONT JAP. Salmon-calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients. Calcif Tissue Int. 1985;37:577-80. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Mayo Clinic Medical School Rochester, Minnesota PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEvaluation and Management of Osteoporosis in Liver DiseaseOsteoporosis in liver diseases and after liver transplantationA controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitisOSTEOPOROSISStabilization and intestinal absorption of human calcitoninPostmenopausal osteoporosis: patient choices and outcomesOsteoporosis: Clinical Features, Prevention, and TreatmentBone disease in cholestatic liver diseaseSkeletal Physiology and OsteoporosisA Rat Model of Thyroid Hormone-Induced Bone Loss: Effect of Antiresorptive Agents on Regional Bone Density and Osteocalcin Gene ExpressionNutritive therapies for osteoporosis: The Role of CalciumBONE DISEASE IN LIVER TRANSPLANT RECIPIENTSEstrogen replacement therapy in women at increased risk for breast cancerOsteoporosisResults of Bone Densitometry Affect Women's Decisions about Taking Measures To Prevent FracturesSusan M. Rubin, MPH, Steven R. Cummings, MDTreatment of established osteoporosis with 1α (OH) vitamin D3 and low dose intermittent elcatonin (eel calcitonin derivative)A new in vitro bioassay for human calcitonin: validation and comparison to the rat hypocalcemia bioassayPostmenopausal osteoporosis: Prevention and treatment with calcitoninOsteoporosis associated with rheumatoid arthritis: Pathogenesis and managementSynthetic human calcitonin in postmenopausal osteoporosis: A placebo-controlled, double-blind studyEstrogen Therapy During Menopause and the Treatment of OsteoporosisMedical Therapy of OsteoporosisModern Therapeutic Approaches to OsteoporosisIssues of Aging in Preventive Medicine and the Example of Osteoporosis 1 December 1987Volume 107, Issue 6Page: 923-925KeywordsCalcitoninCalciumClinical epidemiologyEstrogen replacement therapyEstrogensHip fracturesMorbidityMortalityOsteoporosisPrevention, policy, and public health Issue Published: 1 December 1987 PDF downloadLoading ...